GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (STU:2I9) » Definitions » EV-to-EBIT

Karolinska Development AB (STU:2I9) EV-to-EBIT : 67.14 (As of May. 21, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Karolinska Development AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Karolinska Development AB's Enterprise Value is €30.62 Mil. Karolinska Development AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €0.46 Mil. Therefore, Karolinska Development AB's EV-to-EBIT for today is 67.14.

The historical rank and industry rank for Karolinska Development AB's EV-to-EBIT or its related term are showing as below:

STU:2I9' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.24   Med: -1.1   Max: 82.39
Current: 80.75

During the past 13 years, the highest EV-to-EBIT of Karolinska Development AB was 82.39. The lowest was -8.24. And the median was -1.10.

STU:2I9's EV-to-EBIT is ranked worse than
91.61% of 429 companies
in the Biotechnology industry
Industry Median: 9.96 vs STU:2I9: 80.75

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Karolinska Development AB's Enterprise Value for the quarter that ended in Mar. 2024 was €24.91 Mil. Karolinska Development AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €0.46 Mil. Karolinska Development AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.83%.


Karolinska Development AB EV-to-EBIT Historical Data

The historical data trend for Karolinska Development AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB EV-to-EBIT Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.77 -1.36 5.46 -3.00 67.88

Karolinska Development AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.60 -3.56 -3.53 67.88 77.50

Competitive Comparison of Karolinska Development AB's EV-to-EBIT

For the Biotechnology subindustry, Karolinska Development AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's EV-to-EBIT falls into.



Karolinska Development AB EV-to-EBIT Calculation

Karolinska Development AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=30.616/0.456
=67.14

Karolinska Development AB's current Enterprise Value is €30.62 Mil.
Karolinska Development AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karolinska Development AB  (STU:2I9) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Karolinska Development AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=0.456/24.907461
=1.83 %

Karolinska Development AB's Enterprise Value for the quarter that ended in Mar. 2024 was €24.91 Mil.
Karolinska Development AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karolinska Development AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (STU:2I9) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.

Karolinska Development AB (STU:2I9) Headlines

No Headlines